The biggest breakthroughs are often in cancer R&D. So what’s coming next in oncology? Join PharmaVoice and BioPharma Dive editors on June 5 for a virtual event featuring executives from Merck & Co., Daiichi Sanyko and more to hear about the trends shaping pharma’s future in cancer care.

Novo Nordisk claimed a series of victories last week over obesity market rival Eli Lilly. The FDA accepted the Danish company’s application on Friday for a once-daily oral version of its weekly injectable obesity med Wegovy, and the company could have an approval in hand by the fourth quarter, it said.

If Novo prevails, scoring the first nod for an oral GLP-1 could once again shift momentum in its ongoing rivalry against Lilly. In fact, Lilly overtook Novo for the first time at the beginning of this year, and now controls 53% of the market share, according to the drugmaker’s earnings report released last week. But Novo isn’t landing in second place lying down, recently securing a major PBM win with CVS Health and ramping up its telehealth offerings with more partner platforms. 

We’re digging deeper into the showdown between Lilly and Novo today as the two GLP-1 leaders continue their head-to-head battle. We’re also examining how shifting regulations and economic and trade uncertainties are impacting pharma’s R&D landscape.

Thanks for reading.